Among EGFR-TKIs, erlotinib is currently approved worldwide for the treatment of chemotherapy-resistant advanced NSCLC patients, while the use of gefitinib is restricted to Asian countries. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.